• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Pharmacovigilance Analytics

Your best resource for PV analytics news, content and innovation!

  • Home
  • Pharmacovigilance Analytics
    • Sources of data
    • Methods and tools
  • Signal Detection
  • News
  • Opinion
  • About
  • Glossary

The Pharmacovigilance of the Future: Prospective, Proactive, and Predictive

April 6, 2018 by Jose Rossello 2 Comments

Peter J Pitts, President of the Center for Medicine in the Public Interest, and Hervé Le Louet, President of CIOMS, have just published an intellectually-stimulating essay on the future of pharmacovigilance entitled “Advancing Drug Safety Through Prospective Pharmacovigilance“. The complete reference of the article is: Pitts PJ, Le Louet H. Ther Innov Regul Sci 2018; https://doi.org/10.1177/2168479018766887.

First, the authors point out that we are entering a new era in drug development. To support that statement, they refer to how the FDA is transforming its way of thinking. On the FDA guidelines on collaborative approach for drug development for pediatric rare diseases, the agency proposes new design types for rare diseases, utilizing the example of Gaucher disease. The proposed study design features include: double-blind, controlled, randomized, multi-center, multi-arm, multi-company noninferiority or superiority trial to evaluate the efficacy and safety of product A, B, C…

Other innovative approaches found in the FDA guideline are those related to the use of modeling and simulation to optimize pediatric studies, as for example to predict the effect of a drug in children based on previously known performance in adults, particularly to inform the dosing rationale.

Small frequency of the disease or the outcome under study should never be an excuse for the weaknesses of a study design. As we were taught when studying Epidemiology, if you don’t have enough cases in your center, then you should try a multi-center study. Now, the next frontier is, not only multi-center studies, but multi-company studies.

The pharmacovigilance paradigm is changing and evolving very fast, keeping up with all the new developments in artificial intelligence (AI), the analysis of real world data to obtain real world evidence, and the multiple, really diverse sources of safety information that are available today. According to the authors:

Artificial intelligence will facilitate what the pharmacovigilance ecosystem lacks today – coordinated and efficient systems for developing actionable evidence on safety and effectiveness

The field of artificial intelligence is evolving so rapidly, that I’m convinced we will pretty soon face the paradox of needing AI help for human intelligence to understand what AI is delivering.

To me, the most important point of this paper relies on the subtle comparison between what I would call the ‘old’ pharmacovigilance, which is reactive and non-anticipatory, and the ‘new’ pharmacovigilance, which is proactive in continuously evaluating the benefit-risk profile of a product, elaborating predictive models giving place to predictive pharmacovigilance.

I cannot finish my review without mentioning the most interesting and intriguing section of the paper “Inventing the Pharmacovigilance Future“. In this section, the authors present brilliant ideas they very probably can help to put into practice. I would like to highlight their suggestion of “an international effort under the tripartite chairmanship of the WHO, the ICH, and the CIOMS, to investigate, debate and develop prototype programs for drugs approved via expedited review pathways, based on more sensitive premarket metrics of risk pontential”. And the last, and most intriguing of the concepts presented in this paper, is the Real World Pharmacovigilance Score (RWPS), a baseline prediction of likely adverse events based on projected volume and specific clinical use. Many questions I have about RWPS are not responded in the paper: how is it calculated, do you have any example of application in ‘real world’? I wish they will publish a paper on this matter.

I recommend you to read the essay, eye opening and intellectually challenging.

Jose Rossello
Jose Rossello

Filed Under: News Tagged With: artificial intelligence, predictive pharmacovigilance, real world data

Reader Interactions

Comments

  1. Payal Pawar says

    August 13, 2018 at 4:28 am

    Great Guidance|Thank you for posting the valuable information about Pharmacovigilance And every people easily understand about your posting. This is the best site for Pharmacovigilance guide. your site has a good content which provides good and right information about Pharmacovigilance.I’m very hopful that u will keep sharing this type of articles in near future. Thank You.

    Reply

Trackbacks

  1. Top 7 Predictive Model Applications in Drug Safety and Pharmacovigilance - Pharmacovigilance Analytics says:
    February 24, 2019 at 5:06 pm

    […] basic descriptive analysis towards predictive analysis and the development of predictive models. Predictive analytics uses existing information to make predictions of future outcomes or future trends in all areas of […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Subscribe in a reader

Uses of Generative AI in Pharmacovigilance

Featured News / Posts

Future of Regulatory Compliance: Navigating AI Advancements

As artificial intelligence (AI) continues to evolve and integrate into every … [Read More...] about Future of Regulatory Compliance: Navigating AI Advancements

AI Tools for Pharmacovigilance Data Analysis: Enhancing Drug Safety Monitoring

Artificial intelligence (AI) is revolutionizing the field of pharmacovigilance, … [Read More...] about AI Tools for Pharmacovigilance Data Analysis: Enhancing Drug Safety Monitoring

Predictive Models for Identifying Drug Risks: Enhancing Pharmaceutical Safety

In the field of healthcare, leveraging the power of predictive models to … [Read More...] about Predictive Models for Identifying Drug Risks: Enhancing Pharmaceutical Safety

Introduction to NLP in Pharmacovigilance: Enhancing Drug Safety Monitoring

Natural Language Processing (NLP) has become a pivotal tool in the realm of … [Read More...] about Introduction to NLP in Pharmacovigilance: Enhancing Drug Safety Monitoring

Overview of Machine Learning Models in Pharmacovigilance: Enhancing Drug Safety Monitoring

Pharmacovigilance plays a crucial role in public health by ensuring the safety … [Read More...] about Overview of Machine Learning Models in Pharmacovigilance: Enhancing Drug Safety Monitoring

AI and Real-Time Drug Safety Monitoring: Revolutionizing Pharmacovigilance Practices

Artificial intelligence (AI) is transforming the landscape of drug safety by … [Read More...] about AI and Real-Time Drug Safety Monitoring: Revolutionizing Pharmacovigilance Practices

AI’s Role in Identifying Adverse Drug Reactions: Enhancing Pharmacovigilance Systems

Artificial intelligence (AI) is becoming an indispensable tool in healthcare, … [Read More...] about AI’s Role in Identifying Adverse Drug Reactions: Enhancing Pharmacovigilance Systems

Key AI Technologies in Drug Safety Monitoring: Revolutionizing Pharma Vigilance

The integration of artificial intelligence (AI) technologies into the realm of … [Read More...] about Key AI Technologies in Drug Safety Monitoring: Revolutionizing Pharma Vigilance

Evolution of Drug Safety: Tracing the Shift to AI-Driven Methodologies

Ensuring the safety of pharmaceutical drugs is a complex challenge that has … [Read More...] about Evolution of Drug Safety: Tracing the Shift to AI-Driven Methodologies

Introduction to AI in Drug Safety Monitoring: Revolutionizing Pharmacovigilance

Artificial Intelligence (AI) has emerged as a transformative force in the realm … [Read More...] about Introduction to AI in Drug Safety Monitoring: Revolutionizing Pharmacovigilance

  • The Proportional Reporting Ratio According to ChatGPT
  • Explainable Artificial Intelligence and Pharmacovigilance
  • Analysis Of Textual Data May Complement Traditional Pharmacovigilance

RSS From Nature journal

  • Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro
  • NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease
  • Safety and efficacy of remimazolam compared with midazolam during bronchoscopy: a single-center, randomized controlled study
  • Impact of sex and age on vaccine-related side effects and their progression after booster mRNA COVID-19 vaccine
  • A generative adversarial network model alternative to animal studies for clinical pathology assessment

Copyright © 2023 · News Pro on Genesis Framework · WordPress · Log in